Cullinan Therapeutics(CGEM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CGEM Cullinan Therapeutics

Trading 10-29 15:08:02 EDT

15.49

-0.07

-0.45%

High16.19	Low15.40	Vol241.10K
Open15.60	D1 Closing15.56	Amplitude5.05%
Mkt Cap996.85M	Tradable Cap744.80M	Total Shares64.35M
T/O3.81M	T/O Rate0.50%	Tradable Shares48.08M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CGEM","market":"US","secType":"STK","nameCN":"Cullinan Therapeutics","latestPrice":15.49,"timestamp":1793300872737,"preClose":15.56,"halted":0,"volume":241098,"delay":0,"changeRate":-0.004498714652956317,"floatShares":48082800,"shares":64354694,"eps":-3.468035,"marketStatus":"Trading","change":-0.07,"latestTime":"10-29 15:08:02 EDT","open":15.6,"high":16.185,"low":15.4,"amount":3813995.322852,"amplitude":0.05045,"askPrice":15.51,"askSize":527,"bidPrice":15.47,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-3.468035,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1793304000000},"marketStatusCode":2,"adr":0,"listingDate":1610082000000,"exchange":"NASDAQ","adjPreClose":15.56,"preHourTrading":{"tag":"盘前","latestPrice":15.65,"preClose":15.56,"latestTime":"09:28 EDT","volume":2588,"amount":41177.437668,"timestamp":1793280517072,"change":0.09,"changeRate":0.005784,"amplitude":0.024422},"postHourTrading":{"tag":"盘后","latestPrice":15.367743,"preClose":15.56,"latestTime":"19:31 EDT","volume":14250,"amount":221615.502473,"timestamp":1793230260022,"change":-0.192257,"changeRate":-0.012356,"amplitude":0.032279},"volumeRatio":0.578099,"impliedVol":0.8243,"impliedVolPercentile":0.4343},"requestUrl":"/m/hq/s/CGEM/tweets","defaultTab":"tweets","newsList":[{"id":"2679444900","title":"How Investors May Respond To Cullinan Therapeutics (CGEM) Global Trial Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2679444900","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679444900?lang=en_us&edition=fundamental","pubTime":"2026-10-29 09:18","pubTimestamp":1793236720,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics reported regulatory clearance in the U.S. and Australia to start a global Phase 1b/2a trial of velinotamig in relapsing and refractory ITP and wAIHA, alongside new Phase 2 zipalertinib data in NSCLC with active CNS metastases.\nThe move pushes Cullinan Therapeutics deeper into autoimmune cytopenias while also adding fresh clinical evidence around its EGFR and T cell engager pipeline. This raises practical questions on trial execution, cost allocation, and how management...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgem/cullinan-therapeutics/news/how-investors-may-respond-to-cullinan-therapeutics-cgem-glob","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgem/cullinan-therapeutics/news/how-investors-may-respond-to-cullinan-therapeutics-cgem-glob","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ISBC","BK4211","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679497545","title":"Cullinan’s New AML Trial: What CLN-049’s Phase 1b Combo Study Could Mean for CGEM Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2679497545","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679497545?lang=en_us&edition=fundamental","pubTime":"2026-10-29 00:31","pubTimestamp":1793205102,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics Inc ($CGEM) announced an update on their ongoing clinical study. This Phase 1b study, formally titled A Phase 1b Dose Escalat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cullinans-new-aml-trial-what-cln-049s-phase-1b-combo-study-could-mean-for-cgem-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cullinans-new-aml-trial-what-cln-049s-phase-1b-combo-study-could-mean-for-cgem-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","CGEM","BK4211","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678226461","title":"Cullinan Therapeutics price target raised to $41 from $40 at BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2678226461","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678226461?lang=en_us&edition=fundamental","pubTime":"2026-10-28 19:11","pubTimestamp":1793185893,"startTime":"0","endTime":"0","summary":"BTIG raised the firm’s price target on Cullinan Therapeutics (CGEM) to $41 from $40 and keeps a Buy rating on the shares. The firm cites the compan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cullinan-therapeutics-price-target-raised-to-41-from-40-at-btig-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cullinan-therapeutics-price-target-raised-to-41-from-40-at-btig-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678450082","title":"Cullinan Therapeutics is Maintained at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2678450082","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678450082?lang=en_us&edition=fundamental","pubTime":"2026-10-28 18:05","pubTimestamp":1793181900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGEM/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678358224","title":"Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Verastem (VSTM) and Cullinan Management (CGEM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2678358224","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678358224?lang=en_us&edition=fundamental","pubTime":"2026-10-28 10:01","pubTimestamp":1793152904,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Johnson & Johnson (JNJ), Verastem (VSTM) and Cullina...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-johnson-johnson-jnj-verastem-vstm-and-cullinan-management-cgem-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-johnson-johnson-jnj-verastem-vstm-and-cullinan-management-cgem-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1023059063.AUD","CGEM","IE00BVYPNW00.USD","IE0000B7K699.USD","BK4581","GDOC","IXJ","JNJ","LU0820561818.USD","XBI","LU0128526141.USD","MEDX","LU0162691827.USD","IE00BFXG1179.USD","IHE","BK4568","IE00BJJMRZ35.SGD","LU0553294199.USD","LU2417539215.USD","LU1221951129.SGD","VSTM","LU1674673691.USD","XLV","IYH","LU2487616109.SGD","RXL","FTXH","BK4139","LU0203345920.USD","IE00B7SZLL34.SGD","LU1074936037.SGD","IE00B3T34201.USD","FHLC","LU0738911758.USD","JDOC","BMED","VHT","HCSG","LU0345770308.USD","LU2750360641.GBP","LU2505996509.AUD","LABU","LU0053666078.USD","LU0545562505.USD","LU1032466523.USD","TRUH","LU0689626769.HKD","PJP","BK4592","LU1551013425.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678176307","title":"Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following Ind Clearance by the U.S. FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2678176307","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678176307?lang=en_us&edition=fundamental","pubTime":"2026-10-27 19:00","pubTimestamp":1793098803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nTUAB3NLKX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678176412","title":"Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2678176412","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678176412?lang=en_us&edition=fundamental","pubTime":"2026-10-27 19:00","pubTimestamp":1793098800,"startTime":"0","endTime":"0","summary":"Global regulatory clearances in the U.S. and Australia support initiation of a Phase 1b/2a study in relapsing and refractory ITP and wAIHA Study expands immunology portfolio into autoimmune cytopenias","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/27/3388808/0/en/cullinan-therapeutics-advances-velinotamig-into-global-clinical-development-for-autoimmune-cytopenias-following-ind-clearance-by-the-u-s-fda.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4199","BK4077","LABU","BK4585","BK4588","ITP","CGEM","SLE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677690926","title":"Cullinan’s CLN-978 RA Trial: Early-Stage Catalyst in a Crowded Autoimmune Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2677690926","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677690926?lang=en_us&edition=fundamental","pubTime":"2026-10-21 00:31","pubTimestamp":1792513875,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics Inc ($CGEM) announced an update on their ongoing clinical study. Cullinan Therapeutics Inc. is launching a Phase I trial of C...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cullinans-cln-978-ra-trial-early-stage-catalyst-in-a-crowded-autoimmune-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cullinans-cln-978-ra-trial-early-stage-catalyst-in-a-crowded-autoimmune-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676682159","title":"Cullinan Therapeutics Price Target Maintained with a $40.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2676682159","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676682159?lang=en_us&edition=fundamental","pubTime":"2026-10-19 23:19","pubTimestamp":1792423140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGEM/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676010500","title":"Cullinan's Zipalertinib Shows 30.2% Intracranial Response Rate in Phase 2 Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2676010500","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676010500?lang=en_us&edition=fundamental","pubTime":"2026-10-19 19:06","pubTimestamp":1792407969,"startTime":"0","endTime":"0","summary":"Cullinan's zipalertinib shows 30.2% intracranial response rate in Phase 2 lung cancer trialCullinan Therapeutics and Taiho Oncology announced Phase 2 REZILIENT2 results showing zipalertinib activity a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261019:nNDL3Z39dq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673207962","title":"Cullinan Therapeutics - Expects Phase 1 Cln-049 Study Update in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2673207962","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673207962?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:00","pubTimestamp":1791457202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nTUA93ZXWH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673079567","title":"Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of Cln-049 in Relapsed/Refractory Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2673079567","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673079567?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:00","pubTimestamp":1791457202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nTUA93ZXWH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CGEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673071460","title":"Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2673071460","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673071460?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:00","pubTimestamp":1791457200,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Oct.  08, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/08/3377131/0/en/cullinan-therapeutics-announces-first-patient-dosed-in-planned-registrational-phase-2-study-of-cln-049-in-relapsed-refractory-acute-myeloid-leukemia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KBWY","PD","PK","CGEM","LU1169589451.USD","BK4218","BK4181","LU1169590202.USD","BK4139","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673019803","title":"Cullinan Management (CGEM) Gets a Buy from Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2673019803","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673019803?lang=en_us&edition=fundamental","pubTime":"2026-10-07 22:55","pubTimestamp":1791384959,"startTime":"0","endTime":"0","summary":"Wedbush analyst Robert Driscoll maintained a Buy rating on Cullinan Management today and set a price target of $42.00. According to TipRanks, Drisc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cullinan-management-cgem-gets-a-buy-from-wedbush-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cullinan-management-cgem-gets-a-buy-from-wedbush-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673606807","title":"Cullinan Therapeutics (CGEM) Starts Zipalertinib NDA Submission, Is The Stock Still 52% Undervalued?","url":"https://stock-news.laohu8.com/highlight/detail?id=2673606807","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673606807?lang=en_us&edition=fundamental","pubTime":"2026-10-07 01:25","pubTimestamp":1791307518,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics (CGEM) drew fresh attention after launching a New Drug Application submission for zipalertinib plus platinum chemotherapy, using the FDA’s Real-Time Oncology Review program and Phase 3 REZILIENT3 progression-free survival data.\nCullinan Therapeutics now trades at US$16.04, with the stock gaining 3.42% on a 1-day share price return and 5.32% over seven days, even though the 30-day share price return is down 27.39% and the 90-day return is down 12.97%.\nSet against that...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgem/cullinan-therapeutics/news/cullinan-therapeutics-cgem-starts-zipalertinib-nda-submissio","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgem/cullinan-therapeutics/news/cullinan-therapeutics-cgem-starts-zipalertinib-nda-submissio","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CGEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672103667","title":"Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Cullinan Management (CGEM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672103667","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672103667?lang=en_us&edition=fundamental","pubTime":"2026-10-02 22:00","pubTimestamp":1790949616,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Monte Rosa Therapeutics (GLUE) and Cullinan Manageme...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-monte-rosa-therapeutics-glue-and-cullinan-management-cgem-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-monte-rosa-therapeutics-glue-and-cullinan-management-cgem-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4588","BK4539","LABU","BK4585","XLV","BK4137","LU0029874061.USD","GLUE","BK4139","BK4581","LU0128526141.USD","CGEM","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672716458","title":"Cullinan Therapeutics Price Target Maintained with a $35.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2672716458","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672716458?lang=en_us&edition=fundamental","pubTime":"2026-10-02 18:42","pubTimestamp":1790937720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGEM/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672716160","title":"Cullinan Management Advances NDA for Zipalertinib Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2672716160","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672716160?lang=en_us&edition=fundamental","pubTime":"2026-10-02 18:33","pubTimestamp":1790937182,"startTime":"0","endTime":"0","summary":"An update from Cullinan Management ( ($CGEM) ) is now available. On October 1, 2026, Cullinan Therapeutics announced it had initiated a New Drug Ap...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cullinan-management-advances-nda-for-zipalertinib-combination?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cullinan-management-advances-nda-for-zipalertinib-combination?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672154237","title":"Cullinan Initiates FDA NDA Submission for Zipalertinib Plus Chemotherapy Under RTOR Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2672154237","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672154237?lang=en_us&edition=fundamental","pubTime":"2026-10-02 18:03","pubTimestamp":1790935425,"startTime":"0","endTime":"0","summary":"Cullinan initiates FDA NDA submission for zipalertinib plus chemotherapy under RTOR programCullinan initiated an FDA Real-Time Oncology Review NDA submission for zipalertinib with platinum chemotherap","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDLbYh2Cs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672790775","title":"Cullinan Starts FDA Submission for Zipalertinib-Chemotherapy Combo in Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2672790775","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672790775?lang=en_us&edition=fundamental","pubTime":"2026-10-02 16:10","pubTimestamp":1790928630,"startTime":"0","endTime":"0","summary":"Cullinan Therapeutics  has started submitting its new drug application to the US Food and Drug Administration for zipalertinib plus platinum-based chemotherapy in previously untreated non-small cell lung cancer,  the company said late Thursday.The filing is being reviewed under the FDA's Real-Time Oncology Review program, which allows regulators to assess clinical data ahead of a full application.The submission is supported by results from a phase 3 trial showing a significant progression-free survival benefit over chemotherapy alone, the company said.Cullinan expects to complete the regulatory submission by year-end 2026.The company is eligible for milestone payments of $30 million and $100 million tied to potential second-line and first-line approvals, respectively, it said.Cullinan said Zipalertinib remains an investigational drug and has not been approved by any health authority.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CGEM","BK4139","BK4588","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cullinantherapeutics.com","stockEarnings":[{"period":"1week","weight":0.045},{"period":"1month","weight":0.0408},{"period":"3month","weight":-0.1119},{"period":"6month","weight":0.1586},{"period":"1year","weight":0.8327},{"period":"ytd","weight":0.5034}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":0.0088},{"period":"3month","weight":0.0413},{"period":"6month","weight":0.0717},{"period":"1year","weight":0.1241},{"period":"ytd","weight":0.1326}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cullinan Oncology, Inc. a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer. Its products also include CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors; and CLN-418, a human bispecific antibody that is in Phase 1 clinical trial for the treatment of solid tumors. In addition, the company's preclinical product includes CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.097052},{"month":2,"riseRate":0.666667,"avgChangeRate":0.069507},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.100308},{"month":4,"riseRate":0.333333,"avgChangeRate":0.044053},{"month":5,"riseRate":0.666667,"avgChangeRate":0.039338},{"month":6,"riseRate":0.5,"avgChangeRate":-0.027852},{"month":7,"riseRate":0.5,"avgChangeRate":-0.004001},{"month":8,"riseRate":0.5,"avgChangeRate":0.087786},{"month":9,"riseRate":0,"avgChangeRate":-0.173118},{"month":10,"riseRate":0.666667,"avgChangeRate":0.073893},{"month":11,"riseRate":0.2,"avgChangeRate":-0.037651},{"month":12,"riseRate":0.2,"avgChangeRate":-0.046792}],"exchange":"NASDAQ","name":"Cullinan Therapeutics","nameEN":"Cullinan Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cullinan Therapeutics(CGEM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cullinan Therapeutics(CGEM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cullinan Therapeutics,CGEM,Cullinan Therapeutics股票,Cullinan Therapeutics股票老虎,Cullinan Therapeutics股票老虎国际,Cullinan Therapeutics行情,Cullinan Therapeutics股票行情,Cullinan Therapeutics股价,Cullinan Therapeutics股市,Cullinan Therapeutics股票价格,Cullinan Therapeutics股票交易,Cullinan Therapeutics股票购买,Cullinan Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cullinan Therapeutics(CGEM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cullinan Therapeutics(CGEM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction